RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Pacific Biosciences of California Stock

Pacific Biosciences of California EBIT 2024

Pacific Biosciences of California EBIT

-259.46 M USD

Ticker

PACB

ISIN

US69404D1081

WKN

A1C3EQ

In 2024, Pacific Biosciences of California's EBIT was -259.46 M USD, a -19.42% increase from the -321.99 M USD EBIT recorded in the previous year.

The Pacific Biosciences of California EBIT history

YEAREBIT (undefined USD)
2029e-
2028e-
2027e-
2026e-
2025e-
2024e-
2023-
2022-
2021-
2020-
2019-
2018-
2017-
2016-
2015-
2014-
2013-
2012-
2011-
2010-
2009-
2008-
2007-
2006-
2005-

Pacific Biosciences of California Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Pacific Biosciences of California, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Pacific Biosciences of California from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Pacific Biosciences of California’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Pacific Biosciences of California. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Pacific Biosciences of California’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Pacific Biosciences of California’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Pacific Biosciences of California’s growth potential.

Pacific Biosciences of California Revenue, EBIT and net profit per share

DatePacific Biosciences of California RevenuePacific Biosciences of California EBITPacific Biosciences of California Net Income
2029e612.05 M undefined0 undefined-8.33 M undefined
2028e441.02 M undefined-73.01 M undefined-83.34 M undefined
2027e386.64 M undefined-121.81 M undefined-105.57 M undefined
2026e330.87 M undefined-164.76 M undefined-153.07 M undefined
2025e244.82 M undefined-207.53 M undefined-203.1 M undefined
2024e183.94 M undefined-259.46 M undefined-254.59 M undefined
2023200.52 M undefined-321.99 M undefined-306.74 M undefined
2022128.3 M undefined-303.5 M undefined-314.2 M undefined
2021130.5 M undefined-179.3 M undefined-181.2 M undefined
202078.9 M undefined-104.4 M undefined29.4 M undefined
201990.9 M undefined-100.5 M undefined-84.1 M undefined
201878.6 M undefined-101 M undefined-102.6 M undefined
201793.5 M undefined-89.8 M undefined-92.2 M undefined
201690.7 M undefined-71.2 M undefined-74.4 M undefined
201592.8 M undefined-52.1 M undefined-31.7 M undefined
201460.6 M undefined-62.9 M undefined-66.2 M undefined
201328.2 M undefined-77.5 M undefined-79.3 M undefined
201226 M undefined-94.3 M undefined-94.5 M undefined
201133.9 M undefined-109.8 M undefined-109.4 M undefined
20101.7 M undefined-140.2 M undefined-140.2 M undefined
2009100,000 undefined-88.1 M undefined-87.7 M undefined
2008900,000 undefined-44.8 M undefined-43.8 M undefined
20072.2 M undefined-23.4 M undefined-21.5 M undefined
20062 M undefined-11.9 M undefined-11.7 M undefined
20051.4 M undefined-10.9 M undefined-10.9 M undefined

Pacific Biosciences of California stock margins

The Pacific Biosciences of California margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Pacific Biosciences of California. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Pacific Biosciences of California.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Pacific Biosciences of California's sales revenue. A higher gross margin percentage indicates that the Pacific Biosciences of California retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Pacific Biosciences of California's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Pacific Biosciences of California's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Pacific Biosciences of California's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Pacific Biosciences of California. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Pacific Biosciences of California's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Pacific Biosciences of California Margin History

Pacific Biosciences of California Gross marginPacific Biosciences of California Profit marginPacific Biosciences of California EBIT marginPacific Biosciences of California Profit margin
2029e28.03 %0 %-1.36 %
2028e28.03 %-16.55 %-18.9 %
2027e28.03 %-31.5 %-27.3 %
2026e28.03 %-49.79 %-46.26 %
2025e28.03 %-84.77 %-82.96 %
2024e28.03 %-141.06 %-138.41 %
202328.03 %-160.58 %-152.97 %
202241.08 %-236.55 %-244.89 %
202145.13 %-137.39 %-138.85 %
202041.32 %-132.32 %37.26 %
201938.06 %-110.56 %-92.52 %
201831.93 %-128.5 %-130.53 %
201737.11 %-96.04 %-98.61 %
201648.73 %-78.5 %-82.03 %
201557.65 %-56.14 %-34.16 %
201438.61 %-103.8 %-109.24 %
201322.7 %-274.82 %-281.21 %
20123.46 %-362.69 %-363.46 %
201138.35 %-323.89 %-322.71 %
2010100 %-8,247.06 %-8,247.06 %
2009100 %-88,100 %-87,699.99 %
200828.03 %-4,977.78 %-4,866.67 %
200728.03 %-1,063.64 %-977.27 %
200628.03 %-595 %-585 %
200528.03 %-778.57 %-778.57 %

Pacific Biosciences of California Aktienanalyse

What does Pacific Biosciences of California do?

Pacific Biosciences of California Inc is an American biotechnology company specializing in the development of systems for DNA sequencing and genome research. The company was founded in 2004 and is headquartered in Menlo Park, California. The company was founded by biochemist Stephen Turner, who had previously worked at Illumina, a leading company in genome research. The goal was to develop a new technology for DNA sequencing that would be faster and more accurate than existing systems. In 2005, the company received investments from notable venture capitalists such as Mohr Davidow Ventures, Alloy Ventures, and Kleiner Perkins Caufield & Byers. In 2010, Pacific Biosciences released its first commercial DNA sequencing system. The business model of Pacific Biosciences is based on the development and marketing of DNA sequencing systems and related products and services. The company offers standalone devices as well as integrated solutions for genome research to its customers, including research and diagnostic laboratories. Pacific Biosciences focuses on long-term customer relationships and the continuous advancement of its technologies. Pacific Biosciences operates in two main business segments: research and diagnostics. In the research segment, the company offers DNA sequencing systems that help researchers decipher the DNA of individual cells and complex genomes. These systems enable scientists to deepen their understanding of molecular-level biological processes and diseases. In the diagnostics segment, Pacific Biosciences develops solutions for personalized medicine and application in clinical laboratories. The main product of Pacific Biosciences is the PacBio RS II DNA sequencing platform. This system is based on the single-molecule sequencing technology, which offers high accuracy and reading speed. The PacBio RS II is a fully integrated device that performs both DNA preparation and sequencing, simplifying the entire workflow. In addition, Pacific Biosciences also offers a variety of products and services tailored to the needs of its customers. These include DNA extraction kits, sequencing software, and analysis tools. In summary, Pacific Biosciences of California is a biotechnology company specializing in the development of systems for DNA sequencing and genome research. Founded in 2004, the company is headquartered in Menlo Park, California. Pacific Biosciences operates in two main business segments, research and diagnostics, and offers a variety of products and services tailored to the needs of its customers. The main product of Pacific Biosciences is the PacBio RS II DNA sequencing platform, based on single-molecule sequencing technology. Pacific Biosciences of California ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Pacific Biosciences of California's EBIT

Pacific Biosciences of California's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Pacific Biosciences of California's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Pacific Biosciences of California's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Pacific Biosciences of California’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Pacific Biosciences of California stock

How much did Pacific Biosciences of California achieve in EBIT for the current year?

In the current year, Pacific Biosciences of California has achieved an EBIT of -259.46 M USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Pacific Biosciences of California.

How has the EBIT of Pacific Biosciences of California developed in recent years?

The EBIT of Pacific Biosciences of California has increased by -19.418% decreased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Pacific Biosciences of California?

The EBIT of Pacific Biosciences of California is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Pacific Biosciences of California pay?

Over the past 12 months, Pacific Biosciences of California paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Pacific Biosciences of California is expected to pay a dividend of 0 USD.

What is the dividend yield of Pacific Biosciences of California?

The current dividend yield of Pacific Biosciences of California is .

When does Pacific Biosciences of California pay dividends?

Pacific Biosciences of California pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Pacific Biosciences of California?

Pacific Biosciences of California paid dividends every year for the past 0 years.

What is the dividend of Pacific Biosciences of California?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Pacific Biosciences of California located?

Pacific Biosciences of California is assigned to the 'Health' sector.

Wann musste ich die Aktien von Pacific Biosciences of California kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Pacific Biosciences of California from 7/16/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/16/2024.

When did Pacific Biosciences of California pay the last dividend?

The last dividend was paid out on 7/16/2024.

What was the dividend of Pacific Biosciences of California in the year 2023?

In the year 2023, Pacific Biosciences of California distributed 0 USD as dividends.

In which currency does Pacific Biosciences of California pay out the dividend?

The dividends of Pacific Biosciences of California are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Pacific Biosciences of California stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Pacific Biosciences of California

Our stock analysis for Pacific Biosciences of California Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pacific Biosciences of California Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.